Success Story: In Just 15 Days, A Turkish Hospitalist Achieves NIW Approval via Premium Processing, Also Thanks to Our Assistance
Client’s Testimonial:
“I wish I had applied earlier, especially given the current priority dates. Many of my residency colleagues recommended Chen Immigration for their professionalism and strong track record of success. They provided thoughtful guidance and helped me present my past and current work in a way that allowed USCIS to clearly understand its significance. The team was kind, responsive, and open to feedback—always willing to incorporate my suggestions into the drafts. It was an important step in my career, and I felt a great sense of relief throughout the process thanks to their support. I’m truly grateful for their help.”
On April 17th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Hospitalist in the Field of Immunotherapies (Approval Notice).
General Field: Immunotherapies
Position at the Time of Case Filing: Hospitalist
Country of Origin: Turkey
State of Residence at the Time of Filing: New York
Approval Notice Date: April 17th, 2025
Processing Time: 15 days (Premium Processing Requested)
Case Summary:
We are thrilled to announce the successful I-140 approval under the National Interest Waiver (NIW) category for an MD holder who is contributing critical insights at the intersection of patient care, chronic disease pathology, and translational immunotherapy research.
Currently practicing as a hospitalist in the United States, the client’s proposed endeavor focuses on enhancing the understanding of chronic diseases, such as cancer, diabetes, and cardiovascular illnesses, by exploring genetic predispositions, environmental factors, and novel chemopreventive agents. His research aims to improve therapeutic efficacy and reduce public health burdens through innovative, patient-focused strategies.
The petition highlighted his compelling academic and research background, including:
● 175 citations to his body of published work;
● 5 peer-reviewed journal articles and 6 conference abstracts, including publications in top-tier journals in immunology and nuclear medicine;
● A track record of peer-reviewed contributions, with his work being cited in studies across diverse domains such as antiviral therapy, radiopharmacy, and cancer diagnostics.
Notably, one of his articles ranks in the top 10% most cited in the field of Clinical Medicine for its year, underscoring the broad influence of his research. His work has been utilized by peers developing imaging techniques and treatment strategies in both infectious disease and oncology contexts.
The petition also demonstrated that his endeavors align with U.S. interests in advancing critical and emerging technologies, including synthetic biology and genome engineering. His expertise in areas such as monoclonal antibody production and next-generation sequencing further validated his positioning as a key contributor to national healthcare innovation.
Thanks to his proven impact and continued dedication to advancing life-saving medical science, his NIW petition was approved in just 15 days through premium processing, without the need for additional evidence.
We extend our congratulations and look forward to his ongoing contributions to public health and translational medicine.